The need to study dynamic biologic processes in intact smallanimal models of disease has stimulated the development of highresolution nuclear imaging methods. These methods are capable of clarifying molecular interactions important in the onset and progression of disease, assessing the biologic relevance of drug candidates and potential imaging agents, and monitoring therapeutic effectiveness of pharmaceuticals serially within a single-model system. Single-photon-emitting radionuclides have many advantages in these applications, and SPECT can provide 3-dimensional spatial distributions of g-(and x-) ray-emitting radionuclide imaging agents or therapeutics. Furthermore, combining SPECT with CT in a SPECT/CT system can assist in defining the anatomic context of biochemical processes and improve the quantitative accuracy of the SPECT data. Over the past decade, dedicated small-animal SPECT and SPECT/CT systems have been developed in academia and industry. Although significant progress in this arena has been realized through system development and biologic application, further innovation continues to address challenges in camera sensitivity, spatial resolution, and image reconstruction and quantification. The innumerable applications of small-animal SPECT and SPECT/CT in drug development, cardiology, neurology, and oncology are stimulating further investment in education, research, and development of these dedicated small-animal imaging modalities. Rapi dly evolving knowledge of molecular biology has stimulated exploration of novel therapies targeting specific points in molecular pathways associated with cardiac disease, neurologic disorders, cancer, and many other pathologic processes. However, identifying the role of a molecule in a disease process modeled in vitro does not necessarily translate to an understanding of its interactions with other molecular processes in vivo. On the other hand, few of all disease processes can be fully studied in human patients because of logistical and ethical concerns. Small-animal models represent a critical bridge between discoveries at the molecular level and implementation of clinically relevant diagnostics or therapeutics. Emphasis is ever increasing that these models accurately recapitulate both the disease itself and the environment in which the key molecular processes take place. For example, xenograft mouse models of cancer are simple to develop but are not considered particularly useful in understanding molecular interactions involved in carcinogenesis. More sophisticated approaches, such as transgenic models using oncogene activation or tumor suppressor inactivation, have evolved to the point at which cancers may be induced in a spatially and temporally defined manner using deletion of specified genetic sequences with Cre recombinase (1,2). Sophisticated infrastructures have been developed to manage data related to small-animal models of disease and provide greater access to various mouse models for all investigators, exemplified by the Mouse Models of Human Cancer Consortium sponsored by the National Institutes of Health (3) (information is available at http://mouse.ncifcrf.gov/).
Rapi dly evolving knowledge of molecular biology has stimulated exploration of novel therapies targeting specific points in molecular pathways associated with cardiac disease, neurologic disorders, cancer, and many other pathologic processes. However, identifying the role of a molecule in a disease process modeled in vitro does not necessarily translate to an understanding of its interactions with other molecular processes in vivo. On the other hand, few of all disease processes can be fully studied in human patients because of logistical and ethical concerns. Small-animal models represent a critical bridge between discoveries at the molecular level and implementation of clinically relevant diagnostics or therapeutics. Emphasis is ever increasing that these models accurately recapitulate both the disease itself and the environment in which the key molecular processes take place. For example, xenograft mouse models of cancer are simple to develop but are not considered particularly useful in understanding molecular interactions involved in carcinogenesis. More sophisticated approaches, such as transgenic models using oncogene activation or tumor suppressor inactivation, have evolved to the point at which cancers may be induced in a spatially and temporally defined manner using deletion of specified genetic sequences with Cre recombinase (1, 2) . Sophisticated infrastructures have been developed to manage data related to small-animal models of disease and provide greater access to various mouse models for all investigators, exemplified by the Mouse Models of Human Cancer Consortium sponsored by the National Institutes of Health (3) (information is available at http://mouse.ncifcrf.gov/).
For many years, studies of small-animal models relied on tissue sectioning and microscopy or, in the case of radionuclide-based assays, tissue g-counting and autoradiography after euthanasia. These methods limited the ability of researchers to study a single animal serially over time and required the tedious assembling of histologic or autoradiographic sections. In essence, the assembly of multiple snapshots from different animals was assumed to accurately represent a continuous molecular process. These limitations are now being overcome through the use of molecular imaging to study dynamic biologic processes in smallanimal models of disease. Single-photon-emitting radionu-clides have many advantages in these applications, including a range of half-lives, relatively simple radiolabeling chemistry, low cost, and broad availability. Nuclear imaging follows these tracers at nanomolar and picomolar levels to explain molecular interactions important in the onset and progression of disease, to investigate the biologic relevance of drug candidates and potential imaging agents in streamlined development methodologies, and to monitor the therapeutic effectiveness of pharmaceuticals within a single-model system. Over the past decade, the growth in these nuclear imaging applications has motivated academic and industrial development of both SPECT and PET systems designed specifically for small-animal imaging, with both becoming widely available and affordable. PET is well suited for small-animal imaging, possessing a high detection sensitivity and spatial resolution typically in the range of 1-2 mm. Importantly, PET extends use of 18 F-FDG and other positron-labeled biologic tracers into the preclinical realm as a biomarker for pharmaceutical development and for metabolic studies in the biologic sciences.
SPECT also has several characteristics well suited for small-animal imaging. For instance, SPECT records g-rays directly after radionuclide emission, thereby gaining a theoretic advantage in spatial resolution over PET, for which resolution is currently limited by fundamental processes of positron emission and annihilation. SPECT also has the unique capability of imaging multiple probes labeled with different isotopes, thereby allowing the simultaneous study of multiple molecular or cellular events (Fig.  1) . SPECT uses many radiopharmaceuticals widely applied in clinical nuclear medicine and therefore can be obtained from central radiopharmacies. In many cases, if a desired radiopharmaceutical is not commercially available or in clinical use, a relatively simple laboratory setup is required to produce such tracers using single-photon radiochemistry. Finally, small-animal SPECT studies generally cost less than other small-animal imaging methods, such as smallanimal PET or small-animal MRI.
In this article, we review the current status of small-animal SPECT/CT design, quantitative ability, detector configurations, and various camera performances in the context of a sampling of applications in drug development, cardiology, neurology, and oncology.
BACKGROUND System Design
Although progress in the development and application of small-animal SPECT has been rapid to date, further innovation continues to address challenges in camera sensitivity, spatial resolution, and image reconstruction and quantification. The earliest small-animal SPECT systems were configured from a single scintillation camera operated with a collimator with a single pinhole aperture ( Fig. 2A) . These systems required scan times approaching 1 h, with levels of radioactivity (e.g., .37 MBq [.1 mCi] of 99m Tc) that delivered relatively high levels of radiation dose to the animal. Small-animal SPECT still generally relies on pinhole collimation to achieve millimeter or submillimeter spatial resolution, but there is a trade-off between high resolution and lower sensitivity when using pinhole collimation secondary to the limited number of photons allowed through the pinhole to the face of the detector (Figs. 2C and 2D ). The sensitivity of the single-pinhole system depends on the pinhole size but is typically only on the order of 1% or less for even large pinholes (e.g., 3 mm (4)). Systems with multiple detectors and effective use of the detector area with multipinhole collimators (Fig. 2B ) have improved the trade-off between spatial resolution and detection sensitivity, increasing acquisition speed and enhancing volume localization for small foci of g-emitting agents within the subject volume. However, the sensitivity of small-animal SPECT may never reach the sensitivity of small-animal PET (currently on the order of 1%-10% for commercial imaging systems).
Tomographic Reconstruction
In the clinic, SPECT traditionally has been performed by acquiring planar projection data with parallel-hole collimation at multiple angles around the object and then recon-FIGURE 1. Coregistered in vivo micro-SPECT/CT images of 201 Tl to assess myocardial perfusion and 99m Tc-NC100692 targeted at a v b 3 integrin to identify angiogenesis in wild-type and matrix metalloproteinase 9 (MMP-9) null mice. 99m Tc-NC100692 micro-SPECT images (red) are fused with 201 Tl (green) and CT (gray) images to define uptake of a v b 3 -targeted radiotracer relative to 201 Tl perfusion defect and anatomic structures within chest (CT performed with both 99m Tc and 201 Tl data provides template for fusion). Boxed areas on left are magnified on right. Increased 99m Tc-NC100692 uptake is seen in anterior-lateral infarct territory (arrows) and 99m Tc-NC100692 activity associated with angiogenesis at thoracotomy site (*), demonstrating importance of simply knowing location of sternum as indicated on CT. 99m Tc-NC100692 uptake also was noted in liver. (Reprinted with permission of (117).) structing 3-dimensional cross-sectional images using analytic techniques such as the well-known filtered backprojection (FBP) algorithm. However, small-animal SPECT typically relies on pinhole collimators that acquire projection data with cone-beam, rather than parallel-beam, geometry. Early small-animal SPECT systems used a tomographic reconstruction method known as the Feldkamp-Davis-Kress (FDK) algorithm (5), an analytic technique for reconstructing data acquired with cone-beam geometries, akin to reconstruction of parallel-beam data with FBP. However, because of the susceptibility of the FDK algorithm to propagation of noisy projection data and resulting streak artifacts and the degradation in spatial resolution resulting from a frequent need to apply a smoothing filter to decrease noise that passes the ramp filter in the algorithm, the FDK method has been generally replaced by iterative methods that model the physics of the acquisition process in the reconstruction algorithm.
A circular orbit with a pinhole collimator does not fully sample the object in the same way as is achieved with parallel-hole or fanbeam collimators. If uncorrected, the incomplete sampling can lead to incomplete projections, axial blurring, and image artifacts. Iterative reconstruction methods can account for the geometry of acquiring pinhole projection data, and more accurate sampling of the object can be obtained with alternative acquisition methods including those using multipinhole collimators, multiple detectors, and noncircular or helical orbits (6) . Iterative reconstruction algorithms also can model the process of g-ray penetration through the edges of the pinhole aperture (6) (7) (8) and thereby restore spatial resolution loss from septal penetration when using high-energy, photon-emitting radionuclides. Finally, iterative algorithms can compensate the radionuclide data for parallax errors and errors in positioning individual events when g-rays strike the detector surface at oblique angles. Iterative reconstruction now is the dominant method of image reconstruction for both preclinical and clinical SPECT, because of its ability to recover or correct for some imagedegrading effects and to generally offer images of higher visual quality and better quantitative accuracy than analytic reconstruction methods (9, 10) . Commercial small-animal SPECT systems typically claim up to submillimeter resolution using iterative reconstruction, but reconstructed resolutions based on FBP are more easily compared between systems.
SPECT/CT
SPECT can be combined with CT in an integrated smallanimal imaging system (including some with PET as a third modality). The CT component of the SPECT/CT system is mounted in line with the SPECT, and both typically share a gantry. In most cases the CT consists of a microfocus x-ray tube source (tube current on the order of 1 mA at 50 kVp) and an x-ray detector (e.g., a charge-coupled device or a complementary metal oxide semiconductor with pixels on the order of 50 mm) with reconstructed resolutions below 100 mm. Alteration of tube voltages (e.g., range, 45-65 kVp) theoretically provides flexibility in contrast for soft tissues, and some success has been reported with contrast agents (11) . Scanning may be helical or stepwise. CT reconstruction uses ray-tracing-based FBP.
SPECT/CT systems allow the radionuclide and CT data to be acquired and coregistered with minimal movement of the subject, often using a completely automated image registration method. CT provides excellent gross anatomic localization. The combination of SPECT with CT will likely be essential for the development of, and future use of, single- photon-emitting probes. SPECT/CT will allow the anatomic localization and quantification of small amounts of increasingly specific radiolabeled probes taken up within the myocardium, small tumor metastases, neurologic system, or other anatomic structures in small-animal models of biology and disease. For example, new methods aiming for absolute quantification of molecular probes have coregistered a SPECT dataset with CTand have used a segmentation algorithm based on CT density levels to determine endocardial edges (12) . Similar quantitative techniques also are being applied and developed for dosimetry and other applications in oncologic imaging and for in vivo pharmacokinetic assessment of new diagnostic and therapeutic agents.
In addition, just as in clinical applications, correlated structural data from CT images also can be used to derive a transmission map for object-specific attenuation correction. Typically, CT image values are converted to linear attenuation coefficient values using calibration curves obtained by imaging a CT calibration phantom containing multiple materials of known density. The attenuation map is then used to model the photon attenuation process in the forward and back projectors of an iterative SPECT reconstruction algorithm.
IMAGE QUANTIFICATION
Quantitative measurements always have presented challenges for SPECT but are vital for a multitude of small-animal imaging applications, such as measuring the dose-response curve for an experimental drug, monitoring tumor regression or recurrence after a novel treatment, or studying the changes in cerebral metabolism after a sensorimotor challenge. The requirements for accurate and quantitative data are complicated by limitations in the instrumentation and imaging process. g-Rays emitted in tissue can be absorbed and scattered before entering the detector. The intrinsic resolution of the scanner can blur the radioactivity distribution and introduce error secondary to partial-volume effect, a phenomenon that arises in a target region whose dimensions are approximately equal to or smaller than the spatial resolution of the imaging system (13) . Further, counting statistics can limit the temporal resolution of the detection system. For the measured activity to be a good approximation of the true distribution, many of these effects can be corrected (such as attenuation correction) or improved (such as resolution recovery in the reconstruction algorithm).
In human imaging, physical effects such as photon attenuation and scatter radiation can significantly perturb the quantitative accuracy of the SPECT data. However, whereas the small size of the animal presents a challenge to the instrumentation, it also has some benefits for quantitative measurements. Most notably, g-rays traverse shorter tissue paths and thereby experience significantly less attenuation and scatter in mice and rats than in humans. This raises the fundamental question of whether scatter or attenuation correction is necessary in small-animal SPECT or whether these corrections are more apt to introduce unnecessary noise. Although only modest levels of attenuation are expected from small animals (usually rodents), this process still introduces a measurable error in relating the density of detected photons to the concentration of the radiopharmaceutical in an organ. The attenuation of detectable photons by soft tissue is estimated to be up to 50% when imaging 125 I and up to 25% when imaging 99m Tc in rat-sized objects (14) . Simulation studies suggest that for many isotopes, scatter may contribute approximately 20%-25% to the total counts in a rodent-sized object (14, 15) . However, in the case of 99m Tc, less than 10% of all photons are probably scattered in rodent-sized objects. The effect of scatter is highly dependent on the geometry of both the source and the surrounding materials, but generally, compared with other sources of quantitative error in small-animal SPECT, scatter effect is not a substantial contributor to error. In addition, the overestimation errors typically resulting from scatter are offset by the relatively large underestimation errors caused by photon attenuation and partial-volume effects (14) .
Correcting SPECT images for the effects of photon attenuation in tissue is relatively straightforward, either by using postprocessing of the images to extract an animal boundary or by, more accurately, using an external radiation source to map the attenuation distribution of the animal. Both processes can be performed by acquiring a CT scan of the animal immediately before or after the SPECT scan, with the animal in the same position during both SPECT and CT (15) . Dualmodality SPECT/CT systems clearly simplify this process (16, 17) . The anatomic data from CT also could be used to correct the lower-resolution SPECT images for partialvolume effects, but, as is the case with radiographic imaging modalities in general, the poor soft-tissue contrast resolution of small-animal CT scanners may make this difficult in practice. Investigators also are developing methods to correct for scattered radiation.
Once the images are recorded as accurately as possible within the constraints of the equipment, extracting quantitative data that have physiologic relevance is a further complication. Tracer kinetic modeling provides the link between the distribution of radioactivity in tissue over time and the relevant physiologic parameters associated with a particular organ or disease state. This type of study generally requires rapid arterial blood sampling to provide the input function that drives the model. Obtaining arterial blood from small animals, such as mice (18) and rats (19) (20) (21) , is challenging, particularly given their small total blood volume.
Simplified techniques for obtaining the arterial input function from the imaging data have been developed, such as measuring the blood-pool activity in the left ventricle at the same time as the organ of interest (22) (23) (24) (25) (26) (27) . Unfortunately, this has been limited to PET, because the axial field of view (FOV) of most pinhole SPECT systems is insufficient to include both the heart and another organ. Multipinhole systems may provide sufficient sensitivity and FOV to accommodate this technique, and a more recent small-animal SPECT system, based on slit apertures rather than pinholes, may provide an opportunity for larger FOV imaging (28) .
APPLICATION-BASED DESIGN REQUIREMENTS FOR SMALL-ANIMAL SPECT AND SPECT/CT Drug Discovery and Evaluation
The preclinical validation of drug targeting, safety, and efficacy is strongly driving the use of small-animal SPECT in drug development. Drug-occupancy studies, often used in the evaluation of neurologic pharmaceuticals to understand the selectivity of drug binding in specific regions of the brain and the dependence of pre-and postsynaptic binding on endogenous levels of agonists (29), require repeated imaging of the binding of a drug to a receptor in a single animal in the presence of endogenous or exogenous ligands (30) . The quantitative ability of SPECT in this application has been used in measuring 123 I-N-v-fluoropropyl-2b-carbomethoxy3b-(4-iodophenyl)-nortropane ( 123 I-FP-CIT) binding to dopamine transporters (DATs) in the rat brain after treatment with methylphenidate (31) . SPECT also can help to validate the animal models themselves by evaluating the expression of various receptors or other targets of drug development in the animal's organ of interest.
In some cases, the temperospatial binding profiles of drugs can assist in predicting therapeutic outcome. Small-animal SPECT or SPECT/CT can assist in determining whether the biodistribution and pharmacokinetics of a radiolabeled form of a novel therapeutic drug (or novel imaging agent) are favorable for moving into clinical trials, and such methods have evaluated delivery via hematogenous, oral, and respiratory routes (32) (33) (34) . Drugs also may be linked with moieties to guide their targeting or packaged in vehicles for more specific delivery. Small-animal SPECT has been used to identify the migration of 99m Tc-labeled liposomes after intratumoral administration (35) and to study specific skeletal targeting of 125 I-labeled N-(2-hydroxypropyl)methacrylamide copolymer drug-delivery conjugates after intravenous administration (36) . SPECT can be included in a multimodality small-animal imaging regimen to compare the location of the vehicle with the location of the drug in vivo. SPECT has been used in this manner to monitor macrophage carrier trafficking with colocalization of a fluorescently labeled nanoparticle loaded with antiretroviral therapy for HIV using ex vivo microscopy (37) . As drug delivery becomes ever more targeted, the relationship between the biodistribution of the vehicle and the drug will remain important because the separation of the 2 in vivo can lead to failure of therapy in the clinic. Clearly, innovations in small-animal SPECT/CT technology will affect the speed of acquisition with ramifications for biodistribution and pharmacokinetic studies as well as image quantification. When kinetic models are necessary, current small-animal SPECT is limited in its temporal resolution, and small-animal PET remains a more applicable tool for such kinetic studies (38) .
Because of its ability to measure the functional response of organs to a candidate therapy, small-animal SPECT can be used to understand the possible toxicities or secondary biochemical changes of a treatment or to explain observations seen in human clinical trials. For example, to investigate a potential connection between an administered therapy and aberrant blood pressures experienced by some patients in a recent phase I clinical trial of an experimental chemotherapy, SPECT/CT with 99m Tc-annexin V was used to investigate whether the therapy was associated with cardiac apoptosis when administered to rat models (39) .
The development and validation of imaging-based surrogate measurements, or biomarkers, for eventual use in clinical trials will likely be an area of growth for smallanimal SPECT and SPECT/CT. In general, biomarkers have some biologic link to the process of the disease and changes in their levels may or may not parallel the severity or progression of the disease itself. By rendering a biomarker capable of being measured by a noninvasive means (e.g., radiolabeling it with a single-photon-emitting radionuclide for SPECT), it can be physically sampled less often. Smallanimal SPECT can indirectly observe the therapeutic actions of pharmaceuticals (e.g., changes in receptor availability or changes in various surrogate markers) by imaging radiolabeled analogs of biomarkers and provide insight as to whether imaging can be used to monitor biomarkers of treatment failure or response in clinical trials (40) . For example, 123 I-CIT SPECT of DAT function can act as a marker of the status of the nigrostriatal dopaminergic system during dopaminergic therapy for Parkinson disease (41) . Small-animal SPECT can be helpful in understanding the dynamics of the target so that fluctuations in drug binding secondary to changes in expression of the binding site are not mistaken for resolution or progression of the disease itself, as may be seen in DAT imaging (42) .
Other molecular indicators of mechanism or efficacy that have been measured in human and small-animal studies using SPECT include regional cerebral blood flow in the brain (38, 43, 44) , temporal and spatial parameters of 111 Inlabeled lymphocyte homing in inflammatory bowel disease (45) , early neuronal ischemic injury levels evidenced by 99m Tc-hydrazinonicotinic-annexin V in acute stroke (46) , and uptake of 99m Tc-hydrazinonicotinic-annexin V indicating apoptosis in malignancy (47) . Objective, reproducible, and safe imaging-based biomarkers for SPECT will require substantial research. Clearly, the optimal situation is one in which a surrogate marker can be developed, standardized, and used in preclinical animal studies and can be carried through human trials. Small-animal SPECT promises to facilitate the translation of radiopharmaceuticals from mouse to human. The limiting factors in this development will be the relatively slow acquisition time of SPECT, which may be addressed using multipinhole systems. However, resulting improvements in acquisition time will need to be balanced with the potential to decrease levels of administered activity because repetitive use of radionuclide-based imaging bio-markers could have potential ramifications on the biologic processes being studied.
Neurologic Applications
Imaging the brain in small animals with SPECT remains one of the most challenging applications of the modality because of the small size of brain structures, relatively low tracer uptake, and complex kinetics. However, it is also potentially one of the niche applications in small-animal imaging in which SPECT has significant advantages over other functional modalities, particularly PET (13). The main reasons for the advantage of SPECT, compared with PET, in brain imaging are the ability to push the spatial resolution to below 1 mm by fine-tuning the pinhole characteristics, the availability of longer-lived isotopes, and the high specific activity of most no-carrier-added SPECT tracers. Many PET tracers, particularly those labeled with 11 C, have a low specific activity, which may lead to significant occupancy of the target site by the tracer itself and possible pharmacologic effects.
Brain imaging demands the highest possible spatial resolution and sensitivity from equipment. In this application, it is an advantage that the brain is small, so the FOV can be limited to maximize resolution and sensitivity. Because uptake of most tracers in the brain is low (generally ,1%), and accurate quantification generally requires dynamic imaging with good temporal resolution, reasonable counting statistics may demand a high injected dose. Pinhole SPECT can provide accurate and quantitative imaging results from mouse (48, 49) and rat (50) brain studies in the dopaminergic system (Fig. 3) . Combining functional SPECT images with anatomic MRI data is particularly valuable in small-animal studies to delineate substructures within the brain (51, 52) .
Tracking uptake kinetics with brain imaging places further demands on the imaging equipment. Rapid dynamic scans are required to capture the true shape of the time-activity curve, coupled with high spatial resolution to provide adequate separation between the neighboring brain regions. These constraints have led to the development of multipinhole multiple-detector stationary SPECT systems (53, 54) ; because the detectors do not need to rotate around the object, they can capture fast kinetics, which would otherwise be lost or blurred in a rotating scanner. Although the effect of radiation dose on small animals has not been studied in great detail, it is clear that brain-imaging studies may be one of the first applications in which multipinhole SPECT systems are a necessity because of the higher doses required for sufficient counting statistics in dynamic or quantitative SPECT. Indeed, simulation studies have been performed in which the multipinhole configuration is optimized specifically for mouse brain imaging (55) , enabling the radiation dose to be reduced by an order of magnitude.
Cardiovascular Applications
Cardiovascular molecular imaging is an emerging and evolving field that integrates and motivates new imaging technology with the development of new cardiovascular imaging agents (56, 57) . Imaging the heart of a mouse or a rat requires the spatial resolution of pinhole imaging because this organ and its vasculature are small. In addition, the rodent heart beats at a high rate (400-800 beats/min) and moves with every single breath; therefore, acquisition of images must often be performed with cardiac or respiratory gating. Several studies have used gated pinhole SPECT to obtain high-quality myocardial perfusion images in rats (58, 59) . A recent study achieved excellent quantitative accuracy with dedicated small-animal pinhole SPECT for in vivo measurement of small myocardial infarctions in rats (60) . Processed gated SPECT can yield highly reproducible and accurate measurements of left ventricular volumes and ejection fraction in rats (61) . Evaluation of myocardial wall motion abnormalities and myocardial thickening and quantification of myocardial flow reserve will be the next steps to be demanded from pinhole SPECT in small-animal myocardial perfusion studies.
Small-animal SPECT also can aid in the evaluation of new myocardial imaging agents in vivo. However, these tasks require the highest possible level of sensitivity and temporal resolution for dynamic studies, ideally with submillimeter spatial resolution. For example, a study in a rat animal model of myocardial ischemia-reperfusion after left coronary artery occlusion with 99m Tc-glucarate (a novel infarct-avid agent) used rapid sequence 3-dimensional imaging with a custom multidetector, multipinhole SPECT system (FAST-SPECT; University of Arizona) to successfully quantify uptake and washout kinetics of the imaging agent with high resolution and fast dynamic acquisition (62) . Targeting vascular endothelial growth factor receptors and a v b 3 (63-66) for imaging of ischemia-induced angiogenesis has the potential to complement routinely available clinical assessments of myocardial flow and to evaluate therapeutic angiogenic strategies. Apoptosis, or programmed cell death, occurs in many cardiovascular diseases and can be imaged in vivo with annexin V (67) labeled with 99m Tc and other radionuclides. This approach has the potential for identifying an infarct, monitoring reperfusion therapy, or assessing heart transplant rejection (68) . In vivo tracking of stem cells in cardiovascular disease is an exciting new area of research that requires, regardless of the stem cell origin, that the location and number of such cells be tracked, in vivo, over long periods (Fig. 4) . Tracking small numbers of radiolabeled cells in the living body is extremely difficult, and an optimal solution does not yet exist (69) .
One rapidly growing area of cardiovascular molecular imaging is the development of methods to characterize atherosclerotic plaques. All plaques do not carry the same risk of a later adverse myocardial event, and it would behoove physicians to target their interventions to only those plaques that showed biochemical or anatomic signs of potential rupture. Radiolabeled annexin V, Z2D3 (a smooth-musclecell antibody), and inhibitors to matrix metalloproteinases are SPECT agents that target specific pathophysiologic processes associated with atherosclerosis and have been used to characterize plaques in vivo (64, (70) (71) (72) . Anatomic localization and differentiation of plaque types remain challenges for small-animal CT and SPECT/CT because small-animal CT does not yet offer the acquisition speed or spatial resolution needed to image the small and motile coronary vessels of small animals. These represent areas in which profound advances both in imaging technology and in the development of new cardiovascular probes are needed to achieve the full potential of cardiovascular molecular imaging.
Oncologic Applications g-Ray photons from common radionuclides such as 99m Tc easily penetrate the relatively thin soft tissues within the mouse, allowing the detection of molecules expressed around or on the surface of cancers within the animal. Thus, small-animal SPECT complements other molecular imaging modalities, such as optical techniques, particularly in transgenic models in which cancers can be deep within the imaging subject.
The recognition that gene expression is a dynamic phenomenon has increased the importance of characterizing various protein-mediated tumor processes serially in the laboratory. In this role, small-animal SPECT has been used to monitor cancer metastasis using cancer-specific targeting molecules (73) ; angiogenesis mediated by a v b 3 integrin expression with short-peptide radiopharmaceuticals during tumor growth, invasion, and metastasis (74-77); Her-2 expression using a Her-2 affibody (78); and prostatespecific membrane antigen (PSMA) expression levels in prostate cancer (Fig. 5 ) using small-molecule ligands for PSMA (79) . Imaging small-animal models of cancer can illustrate the interaction of the tumor with its microenvironment, but further work is required to generate a sufficient library of imaging agents, because the translation of in vitro assays into SPECT agents is challenging (74) . In the case of chemotherapy planning and evaluation for multidrug resistance, small-animal SPECT/CT has characterized several radiopharmaceuticals used to monitor the expression or activity of the transmembrane p-glycoprotein pump, including 99m Tc tetrofosmin, 99m Tc-sestamibi (80) , and a Schiff base 67 Ga(III) complex (81) , and compared their efflux with that of radiopharmaceuticals resistant to washout by p-glycoprotein-expressing tumors (82) . These types of studies require rapid dynamic small-animal SPECT, similar to the need described earlier. The field of radiation oncology also has shown interest in using functional imaging to better define tumor volumes or characterize FIGURE 4. Cardiac long-and shortaxis SPECT images of normal (A and C) and infarcted (E and G) heart using perfusion tracer 99m Tc-sestamibi (MIBI). Signal from 111 In-labeled stem cells (In, color) was overlaid on gray-scale MIBI images for normal (B and D) and infarcted (F and H) heart. specific sites of poor tissue oxygenation in radiation treatment plans (83) . Small-animal SPECT will play a role in the development of these techniques and in the definition and assessment of therapeutic response.
The ability to engineer tumor cells to express reporter genes, such as the herpes simplex virus type 1 thymidine kinase (HSV1-tk), has enabled noninvasive imaging of tumor cell volumes with a variety of modalities, including SPECT/CT. Once HSV1-tk phosphorylates the substrate 2-fluoro-2-deoxy-5-iodo-1-b-D-arbinofuranosyluracil (FIAU) labeled with 131 I or 123 I, the radiolabeled, monophosphorylated substrate is entrapped within the cell. The concentration of 131 I-or 123 I-FIAU within the tumor cells allows imaging of the location of the cells with SPECT (84) . When imaged with small-animal SPECT, FIAU uptake has demonstrated a high correlation with the percentage of viable tumor cells and has been reliable in predicting response to therapy (85) . When used to quantify protein expression after gene therapy, such as using 111 In-octreotide to monitor the expression of a somatostatin receptor gene therapy, quantitative small-animal SPECT/CT has demonstrated a strong correlation to in vitro g-counting (86) . In some cases, quantification has been improved in SPECT/CT by simply using the anatomic CT images to generate regions of interest instead of relying only on SPECT or planar scintigraphy (87) . In addition to monitoring gene therapies, the effects of other therapies on gene transcription levels may also be measured using SPECT in the future. The use of radiolabeled antisense molecules for analysis of mRNA levels has been proposed (88), but the relatively small numbers of mRNA molecules to target for SPECT will be challenging, requiring high-sensitivity imaging systems.
Small-animal SPECT/CT will become increasingly important for the evaluation and advancement of molecular radiotherapeutics, as has been exemplified in the development of somatostatin receptor ligand analogs (33) , development of folate-based radiopharmaceuticals (89, 90) , and enhancement of radiation dose delivery by adjuvant agents (91) . As more molecular radiotherapeutics are realized and the quantitative accuracy of SPECT improves, some level of imaging-based dosimetry will likely become a requisite for Food and Drug Administration approval. Small-animal SPECT/CT can play a role in studies correlating dose and tumor eradication and dose to nontarget organs and unintended side effects.
ADVANCES IN SYSTEM DESIGN AND INSTRUMENTATION Detector Technologies
The need for high spatial resolution and accurate quantification places technical demands on the performance of the radionuclide detector and the entire small-animal imaging system. Although early small-animal SPECT systems were implemented with clinical scintillation cameras, it is not surprising that imaging detectors have been developed and implemented specifically for small-animal SPECT. Newer dedicated systems for small-animal SPECT have implemented position-sensitive photomultiplier tubes and either segmented or continuous scintillation crystals and increased detector areas for greater magnification (92) (93) (94) (95) . Scintillation cameras with position-sensitive photomultiplier tubes require careful calibration to achieve good spatial uniformity and to correct their inherent pincushion distortion (similar to the calibration needed for block detector readout in PET). Nevertheless, this method has been implemented in several of the currently available small-animal SPECT systems now being marketed.
Some detectors developed for small-animal SPECT now alternatively incorporate semiconductor materials, such as cadmium zinc telluride (CZT) or silicon, as direct converters of g-rays to electric signal. CZT is particularly attractive, as it can be segmented to offer intrinsic spatial resolution as high as approximately 380 mm (16, 96) . Furthermore, CZT can be operated at room temperature with excellent energy resolution, particularly important for imaging low-energy isotopes (e.g., 125 I). High-energy resolution also benefits algorithms 177 Lu. Tumor uptake is difficult to localize on SPECT images (A) but is easily localized anatomically on SPECT/ CT overlay images (B). To quantify uptake of radiopharmaceutical, borders of tumor may be visualized on CT (C). Region of interest is selected on basis of CT (D) and applied to SPECT data (E). Three-dimensional renderings (F; arrow indicates tumor) may be helpful in better understanding anatomic relationships but rarely play role in quantification.
for rejecting scattered counts and simultaneous dual-isotope imaging for photopeaks that are close in energy (e.g., 99m Tc and 123 I). CZT has not been used widely in clinical imaging as it is expensive and offers lower stopping power, yielding proportionally less detection efficiency in comparison with common scintillators such as thallium-doped sodium iodide. Furthermore, CZT can be prone to minute impurities associated with low-energy spectral tailing, pixel dropouts, hot spots, and nonuniform response (97, 98) .
Systems incorporating solid-state transducers, such as silicon avalanche photodiodes in place of photomultiplier tubes, have only recently reached performance levels sufficient for radionuclide imaging but offer a compact and rugged alternative to photomultiplier-based systems. Compact photodiode-based cameras have clinical applications in cardiac SPECT (99) and PET/MRI (100,101). Smallanimal SPECT cameras are being designed (102) but have not yet appeared in commercially available systems.
Designs with Multiple Detectors and Multipinhole Collimators
The sensitivity of a SPECT system having a single detector operated with a single pinhole is relatively poor. For smallanimal imaging, the poor sensitivity requires that compromises be made in the collimator design or imaging protocol to acquire adequate image statistics. One method of obtaining greater sensitivity is simply to inject the animal with additional radioactivity, but this approach may have significant ramifications for the biology being studied. As a first approximation of the levels of radiation to which small-animal tissues are subjected during SPECT studies, Funk et al. (103) used Monte Carlo modeling to derive S values (the S value, used in the MIRD schema (104) , gives the absorbed dose per cumulated activity and per unit mass used) for mouse and rat bodies approximated as homogeneous ellipsoids, tabulated these S values for isotopes commonly used in small-animal imaging, and then used them to estimate the whole-body radiation dose to rodents using levels of radioactivity employed in published experiments and known radiopharmaceutical residence times. These calculations were performed using a central point source geometry to model a radiopharmaceutical with highly specific uptake within an organ or tumor and were then repeated using a homogeneously distributed source to model a radiopharmaceutical with nonspecific distribution. Estimates of whole-body doses in SPECT using examples of radiopharmaceutical doses from rodent studies in the literature ranged from less than 2 cGy (160 MBq of 99m Tc in rats [200-250 g], assuming a biologic half-life of 1 h) to 90 cGy (740 MBq of 99m Tc in 30-g mice, assuming a residence time of 3.2 h, a time similar to that of 99m Tcdiethylenetriamine pentaacetic acid [DTPA] in humans). Whole-body doses to rats were found to be approximately a factor of 10 smaller than those calculated for mice for equivalent doses of radiopharmaceutical. As mice and rats often act only as hosts to xenograft or orthotopic tumor tissues, specific organ doses are often not even relevant; what matters is how the radiation affects the biology of interest (i.e., the effect on the tumor implant or other pathologic process). If anything, the concept of the whole-body dose underestimates the actual dose delivered to critical organs or tissues that are avid for a particular radiopharmaceutical. Many SPECT studies are longitudinal, providing multiple doses of a radiopharmaceutical to image multiple times over the course of a several-day or even a several-month experiment, and the cumulative dose to tissues is likely quite high. Effects on murine gene expression have been documented at doses of 20 cGy (105), and lethal doses on the order of several grays (e.g., doses causing mortality in 50% of mice over 30 d) have been reported to be approximately 7 Gy (106, 107) . Higher amounts of radioactivity also require larger volumes of injectate, which can lead to mechanical overload of the limited cardiovascular volume when dealing with mice (108) .
Given an emphasis on maintaining high-resolution imaging with minimal effect on the biologic system studied, focus has been placed on increasing the detection efficiency of the SPECT system while maintaining or improving spatial resolution. Increasing the diameter of the pinhole improves sensitivity but at the cost of degrading spatial resolution (Fig.  2) . Moving the pinhole closer to the subject increases sensitivity and improves resolution but proportionately reduces the FOV of the system. Consequently, researchers have shifted their attention to multiple detectors surrounding the subject or collimators with multiple pinholes to raise the geometric efficiency for detecting the emitted g-rays. An important feature that distinguishes various designs of multipinhole collimators is whether the projections of the subject overlap, or multiplex, on the detector (Fig. 6 ). Multiplexing has consequences on the signal-to-noise ratio of the system and may make a system prone to artifacts. A nonoverlapping multipinhole system can use an existing clinical SPECT scanner, with absorbing septa placed between the pinholes to prevent cross-talk. This is the basis for the U-SPECT-I system (53), which uses a triple-head g-camera and a custom-built cylindric collimator containing 75 gold pinholes and lead shielding positioned to prevent overlapping projections. The multipinhole design increases the system sensitivity roughly by a factor equal to the number of pinholes, which permits smaller-diameter pinholes (and, hence, better resolution) to be used while still obtaining reasonable counting statistics. Alternatively, by reducing the size of the individual SPECT detectors, it is possible to surround the subject by an array of such systems, each with a single-pinhole collimator. This is the basis for the Fast-SPECT II system (54), which uses 16 modular scintillation cameras to image the subject without any rotation. The main disadvantage of such a system is the increased cost to develop specialized detector modules.
Multiplexing systems that use a multipinhole collimator (up to 20 pinholes) and a single clinical scintillation camera, or systems that combine multipinhole collimators with scalable dedicated modular detectors and multipinhole collimators, have significant advantages, with increased sensitivity, expanded FOV, and improved object sampling. However, the increased counting rate obtained with overlapped multipinhole collimation does not necessarily yield the increased signal-to-noise ratio obtained with nonoverlapping projections, because of the ambiguity in the origin of each detected g-ray (109). Although maximum-likelihoodbased iterative reconstruction algorithms can provide a good estimate of the true activity distribution, there is a penalty imposed on the signal-to-noise ratio caused by the degree of overlap (110).
System Calibration
The high level of performance in small-animal SPECT, similar to SPECT systems used in the clinical setting, requires careful system calibration and quality control. Small-animal SPECT and SPECT/CT systems require precise mechanical alignment of both cameras and collimators with the system gantry. One calibration method for coding geometries has been discussed by Bequé et al. (111) , who identified 7 parameters (e.g., detector angle, detector position, detector offset relative to the axis of rotation) required to accurately define the geometry of a detector rotating on a circular orbit. These authors concluded that all governing parameters could be measured from projection data acquired with 3 or more point sources within the FOV. A method to determine the remaining calibration parameters using a single point source, assuming that the detector tilt and the radius of rotation are known, has been discussed by Metzler et al. (112) . Generally, these alignment measurements are acquired at the factory or by the service engineer to generate calibration parameters that then are recorded in a system file for subsequent calibration of the imaging system and reconstruction algorithm.
Once the system is in use, a quality-control program must monitor spatial resolution, spatial uniformity, energy resolution, and counting-rate response in a way similar to assessments performed for clinical SPECT systems. As it is common for many investigators and laboratories to share a single small-animal SPECT system, there is typically a need to frequently reconfigure the system (e.g., change collimators, alter the radius of rotation) for different tasks. The more frequently such changes are made, the more often will recalibration of the system be required. Whenever possible, an attempt should be made to dedicate the small-animal system to a single investigation. This becomes particularly important in longitudinal studies in which the reproducibility of data between time points can become difficult when there have been interval calibrations or simply mild misalignments secondary to the mechanical stress of multiple collimator changes.
The reliance on iterative reconstruction also introduces another level of calibration for the small-animal SPECT systems. As mentioned previously, iterative reconstruction algorithms can include a model of the imaging system, defined by parameters such as the pinhole-detector distance, the distance between the pinhole and the center of rotation, point-by-point nonuniformities in detector sensitivity (113) , and septal penetration of the pinhole aperture (114) . Traditionally, these factors are introduced by calculating the elements in the system matrix, which relates the counting rate recorded by each detector element to the radionuclide concentration at each point of the reconstruction volume (115) . The system matrix then is incorporated into an iterative algorithm that reconstructs the radionuclide concentrations in the object from the ensemble of data recorded by each detector element at each projection angle. Improvements in spatial resolution translate to a larger system matrix. With recent advances in computational memory (and recent decreases in the cost of memory), even the large system matrices associated with high-resolution pinhole SPECT are typically stored and then retrieved for the iterative reconstruction. As a result, it is important to measure the system matrix carefully and at high precision (particularly when performing high-resolution pinhole SPECT) so that it is not perturbed by statistical uncertainties introduced by inadequate numbers of events. Further, given knowledge of the size and shape of the subject in the scanner from, for example, a CT or transmission scan, additional factors can be incorporated into the system matrix to account for scatter and attenuation of g-rays. These additional factors generally are computed using Monte Carlo simulated data, which can account for inhomogeneous subjects (116) .
CONCLUSION
Over the past decade, dedicated small-animal SPECT and SPECT/CT cameras have been developed in academia and industry. The rapid growth in interest in small-animal SPECT has been driven in large part by demand for streamlined drug development and the need for tools to translate understanding of fundamental molecular processes at the cellular level to clinically relevant therapeutics and interventions. Although significant progress in small- FIGURE 6 . (A) Schematic of nonoverlapping multipinhole system. Object FOV is projected on detector surface through (in this case) 3 pinholes without overlap. Multipinhole design increases system sensitivity roughly by factor equal to number of pinholes. (B) Schematic of overlapping (multiplexed) multipinhole system. Object FOV is projected on detector surface through (in this case) 7 pinholes. In contrast to system in A, there is significant overlap of projections on detector surface in B.
animal SPECT and SPECT/CT has been realized through development and application, further innovation continues to address challenges in camera sensitivity, spatial resolution, and image reconstruction and quantification. Although imaging single-photon-emitting radionuclides with SPECT or SPECT/CT offers several advantages in study flexibility and radiochemistry complexity and costs, small-animal PET is currently the most sensitive and quantitatively accurate nuclear imaging modality. Many of the current shortcomings of small-animal SPECT and SPECT/CT are beginning to be overcome by newer generation SPECT/CT cameras and reconstruction algorithms. The innumerable applications of small-animal SPECT and SPECT/CT in drug development, cardiology, neurology, and oncology necessitate further investment in their research and development and education in guiding their applications. New modalities, such as SPECT/MRI, could offer the advantage of additional anatomic and functional information, generating the next level of multimodality molecular imaging.
